ad image
Grant Will Fund Workforce Development Program for Biopharma Industry

Grant Will Fund Workforce Development Program for Biopharma Industry

Sep 06, 2018PAO-M09-18-NI-001

Alcami and the University of North Carolina Wilmington receive an educational grant.

The program “Partnership for Workforce Development in the Biopharmaceutical Industry” proposed by the University of North Carolina Wilmington (UNCW) consists of a comprehensive laboratory, lecture, and internship series and has been approved by the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) as part of NIMBL’s Project Call 1.0. 

NIMBL is an organization comprising companies, educational institutions, nonprofits and state governments focused on accelerating biopharmaceutical manufacturing innovation, the development of industry standards and worker education and training. NIIMBL's Project Call 1.0 is a program seeking projects designed to address biomanufacturing technology and workforce development issues.

The UNCW Partnership for Workforce Development in the Biopharmaceutical Industry program is being co-developed by UNCW and contract development and manufacturing organization, Alcami. Alcami subject matter experts will serve as the program's teachers. The program recently received a $400,000 educational from NIMBL for being a thorough, well-qualified and innovative approach to workforce development. 

The partnership between Alcami and UNCW was initiated in July 2016 when two courses were developed that focused on preparing students for careers in the pharmaceutical industry.

"We are thrilled to build on the successes of our academic partnership with UNCW and implement the next phase of specialized, practical and scalable curricula to North Carolina students," said Stephan Kutzer, President and Chief Executive Officer, Alcami. "Alcami and UNCW are together advancing the local employment pipeline, with a workforce already trained in biopharmaceutical processes and protocols. Our joint efforts will feed both regional and industry growth and bring safe drugs to market faster as a byproduct."

 

ad image
ad image